Out-licensing
- Out-licensing
- View
Cartexan ® - Chondroitin Sulfate
Chondroitin Sulfate
Mechanism of action
Inmediate delivery:
Full description
Cartexan 400 mg Chondroitin Sulfate is indicated for the symptomatic treatment of ostearthritis of hip and knee
Currently authorized and commercialized in Finland.
Available for oulicensing, under registration in several countries.
Development status
Preregistration
Type of business relationship sought
Bioiberica looks for strategic partnerships on a local/regional basis to distribute its full range of products.
Related reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 22 pages - $500
Feb 2011 - 103 pages - $500
Sep 2011 - 105 pages - $500
Dec 2010 - 50 pages - $500
Dec 2010 - 47 pages - $500
Mar 2011 - 49 pages - $500
Dec 2010 - 45 pages - $500
Jul 2011 - 59 pages - $500
Aug 2011 - 88 pages - $500
Apr 2011 - 94 pages - $500
Licensing contact
Company details
Bioiberica
Bioiberica is a research based pharmaceutical company focused in the research development, manufacturing and marketing of Glycosaminglicans such as Chondroitin, Heparin, Glucosamine & Hyaluronic Acid.
View profileRelated technologies
Related categories
- Therapeutic target
- Musculoskeletal
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us